Phillips-Medisize showing off respiratory device capabilities at DDL2017


Phillips-MedisizePhillips-Medisize will be exhibiting at the Drug Delivery to the Lungs Conference in Scotland next month, providing a chance to further tout its respiratory device capabilities.

The Hudson, Wis.–based contract manufacturer boasts more than 30 years at the forefront of inhalation technology. The company’s experience ranges from feasibility to selecting the right components – all the way through to commercial scale production, including electronics integration.

Phillips-Medisize will also highlight connected health products and services, which involve the complete integration of respiratory devices, connected services and drugs.

“We continue to be very focused on partnerships built on innovation, as well as our continuum of contract services for digital interfaces to maximize the patient and caregiver experience. With the acquisition by Molex, we also vertically integrating electronics into our existing capabilities on respiratory devices,” Phillips-Medisize CTO Bill Welch said in a news release.

The Drug Delivery to the Lungs Conference is Dec. 6–8 at the Edinburgh International Conference Center.

How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.

Register now with the code "TAVR" and save 15% today.

Speak Your Mind